ArticleDrug delivery2017
Curcumin: a calixarene derivative micelle potentiates anti-breast cancer stem cells effects in xenografted, triple-negative breast cancer mouse models.
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Pooled it
- Translational drugs targeting cancer stem cells in triple-negative breast cancer.Molecular therapy. Oncology · 2025Review
- Molecular Mechanisms of Dietary Compounds in Cancer Stem Cells from Solid Tumors: Insights into Colorectal, Breast, and Prostate Cancer.International journal of molecular sciences · 2025Review
- Curcumin Administration Routes in Breast Cancer Treatment.International journal of molecular sciences · 2024Review
- Research progress of exosomes in drug resistance of breast cancer.Frontiers in bioengineering and biotechnology · 2023Review
- Engineered exosomes as drug and RNA co-delivery system: new hope for enhanced therapeutics?Frontiers in bioengineering and biotechnology · 2023Review
- Antitumor Properties of Curcumin in Breast Cancer Based on Preclinical Studies: A Systematic Review.Cancers · 2022Review
- Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy.International journal of nanomedicine · 2022Review
- Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Curcumin: reclaiming the lost ground against cancer resistance.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment.Pharmaceutics · 2020Review
- Metal ion-responsive nanocarrier derived from phosphonated calix[4]arenes for delivering dauricine specifically to sites of brain injury in a mouse model of intracerebral hemorrhage.Journal of nanobiotechnology · 2020Article
- Prevention of breast cancer by dietary polyphenols-role of cancer stem cells.Critical reviews in food science and nutrition · 2020Review
- Gomisin M2 from Baizuan suppresses breast cancer stem cell proliferation in a zebrafish xenograft model.Aging · 2019Article
- Review
- Synthesis of TPGS/Curcumin Nanoparticles by Thin-Film Hydration and Evaluation of Their Anti-Colon Cancer EfficacyFrontiers in pharmacology · 2019Article
- Article
- Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon CancerFrontiers in bioengineering and biotechnology · 2019Article
- The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers.Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease with no approved targeted therapy. Curcumin has shown therapeutic potential against TNBC, but it shows low bioavailability and low efficacy when administered as a free drug. Here we describe a novel vehicle for in vivo delivery of curcumin based on the phosphorylated calixarene POCA4C6. Curcumin-loaded POCA4C6 micelles (CPM) were prepared using the thin-film method and they showed a unilamellar structure with an average particle size of 3.86 nm. The micelles showed high curcumin encapsulation efficiency and loading was based on liquid chromatography-tandem mass spectrometry. Studies with cell cultures suggest that CPM can sustainably release curcumin in a pH-dependent manner. The micelles efficiently inhibited proliferation, invasion, migration and tumor spheroid formation by BT-549 human breast cancer cells. These effects involved increased apoptosis and reduced levels of nuclear β-catenin and androgen receptor. After injection into tumor xenografts, CPM persisted in the tumor tissue and efficiently inhibited tumor growth without causing obvious systemic toxicity. CPM also significantly reduced levels of CD44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.